Articles tagged with: Maintenance Therapy
The National Comprehensive Cancer Network (NCCN) has updated its guidelines for the treatment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid maintenance therapy.
The NCCN guidelines are followed closely by physicians and by many U.S. health insurance companies, which frequently use them when making reimbursement decisions about different cancer treatments.
The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research. A panel of specialists within the myeloma field is responsible for …
Results of a recent, small German study show that donor stem cell transplantation followed by Revlimid maintenance therapy may be feasible in heavily pretreated relapsed or refractory multiple myeloma patients.
“For younger and fit patients, [donor] stem cell transplantation followed by maintenance therapy with [Revlimid] is a reasonable treatment option for patients who have already relapsed [after an autologous stem cell transplant],” said Dr. Nicolaus Kröger of the University Hospital Hamburg-Eppendorf in Germany and lead investigator of the study.
Dr. Philip McCarthy of the Roswell Park Cancer Institute in Buffalo, …
Monday was a big day for me.
After undergoing 36 consecutive weeks of Revlimid, Velcade, and dexamethasone therapy since my stem cell transplant, I was hoping that Monday would be the day I could officially begin my easier-to-tolerate maintenance regimen.
Combination therapy with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), known as RVD, had been tough for me to take over the last few months. My platelet and white blood cell counts had been low and continued to edge down. I was sore and out-of-sorts. My body …
Dr. Michel Attal from the Purpan Hospital in Toulouse, France, presented a review of current maintenance therapies for multiple myeloma during the American Society of Clinical Oncology (ASCO) annual meeting last month.
The focus of Dr. Attal’s presentation was on whether there is evidence to support the use of the novel anti-myeloma agents thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib) as maintenance therapy after initial therapy and stem cell transplantation.
Maintenance therapy refers to a prolonged, and often low-dose, form of treatment given to myeloma patients after …
Currently, there are three major controversies in multiple myeloma patient management: early versus late transplant, treat or observe ‘high-risk’ smoldering myeloma, and whether to use maintenance therapy. The latter is predominantly an issue following autologous stem cell transplantation.
In May, one of the world’s premier medical journals, the New England Journal of Medicine, published three articles about clinical trials comparing Revlimid (lenalidomide) maintenance versus observation. In two of the studies, Revlimid maintenance was given following autologous stem cell transplantation. In the third study, Revlimid maintenance was given following conventional …